Featuring perspectives from Dr Hope S Rugo. (Video Program)
TARGET AUDIENCE
This activity is intended for medical oncologists and other healthcare providers involved in the treatment of breast cancer.
OVERVIEW OF ACTIVITY
Breast cancer (BC) remains the most frequently diagnosed cancer in women, and it is estimated that approximately 234,580 new cases will be identified in the United States in the year 2013 and 40,030 individuals will die from the disease. Advances in screening and prevention have resulted in a steady down-stage migration at the time of disease presentation, such that only 5% of women have identifiable distant metastases at primary diagnosis. Because of this, the number of individuals living with BC has increased substantially, as has the population “at risk” for metastatic or recurrent disease. Depending on the histological subtype, the initial stage of their disease at the time of diagnosis and the subsequent treatment strategy employed, approximately 20% to 80% of these women will develop a distant metastasis within 5 years of their BC diagnosis.
Historically, available treatment options offered little for patients with this incurable disease. However, with the introduction of more effective systemic therapies over the past 20 years, there has been a substantial improvement in clinical outcomes. While the diagnosis and treatment of this disease remains in many ways more advanced than for other solid cancers, challenging issues in the management of metastatic BC (mBC) continue to require refinement. Increasing emphasis is being placed on a “personalized medicine” approach that promises to more effectively identify specific treatments that will benefit the individual, based on specific patient and disease characteristics. In conjunction with this approach researchers are developing novel agents to target additional signaling pathways, with the aim of enhancing the efficacy of existing treatments or overcoming resistance/restoring sensitivity to endocrine therapy, chemotherapy or other biologics.
To assist medical oncologists and other allied BC professionals in keeping informed about these approved and developmental approaches, these proceedings from a case-based CME Grand Rounds presentation introduce the perspectives of 12 renowned investigators on a number of controversial clinical and research issues in the management of mBC.
LEARNING OBJECTIVES
ACCREDITATION STATEMENT
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
CREDIT DESIGNATION STATEMENT
CME credit is no longer available for this issue
HOW TO USE THIS CME ACTIVITY
This CME activity consists of a video component. The participant should watch the video.
CONTENT VALIDATION AND DISCLOSURES
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CME activities. Real or apparent conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
FACULTY — The following faculty (and their spouses/partners) reported real or apparent conflicts of interest, which have been resolved through a conflict of interest resolution process:
Kimberly L Blackwell, MD
Professor of Medicine
Director, Breast Cancer Program
Duke Cancer Institute
Durham, North Carolina
Advisory Committee: Novartis Pharmaceuticals Corporation; Consulting Agreements: Novartis Pharmaceuticals Corporation, Sandoz; Contracted Research: Celgene Corporation, Genentech BioOncology, Roche Laboratories Inc; Speakers Bureau: Genomic Health Inc.
Adam M Brufsky, MD, PhD
Professor of Medicine, University of Pittsburgh
Associate Director for Clinical Investigation
University of Pittsburgh Cancer Institute
Co-Director
Comprehensive Breast Cancer Center
Associate Division Chief
University of Pittsburgh, Department of Medicine
Division of Hematology/Oncology
Pittsburgh, Pennsylvania
Advisory Committee: Roche Laboratories Inc; Consulting Agreements: Celgene Corporation, Genentech BioOncology, Genomic Health Inc, Novartis Pharmaceuticals Corporation; Speakers Bureau: Celgene Corporation, Genentech BioOncology, Novartis Pharmaceuticals Corporation.
Lisa A Carey, MD
Richardson and Marilyn Jacobs Preyer
Distinguished Professor for Breast Cancer Research
Chief, Division of Hematology and Oncology
Physician-in-Chief, North Carolina Cancer Hospital
Associate Director for Clinical Research
Lineberger Comprehensive Cancer Center
Chapel Hill, North Carolina
Advisory Committee, Consulting Agreements and Speakers Bureau: Amgen Inc, Bristol-Myers Squibb Company, Genentech BioOncology, Novartis Pharmaceuticals Corporation, Pfizer Inc, Sanofi; Research Support: Genentech BioOncology, GlaxoSmithKline, Sanofi.
William J Gradishar, MD
Betsy Bramsen Professor of Breast Oncology
Professor of Medicine
Director, Maggie Daley Center
for Women’s Cancer Care
Robert H Lurie Comprehensive Cancer Center
Northwestern University Feinberg School of Medicine
Chicago, Illinois
No real or apparent conflicts of interest to disclose.
Julie R Gralow, MD
Professor, Medical Oncology
Jill Bennett Endowed Professorship in Breast Cancer
University of Washington School of Medicine
Director, Breast Medical Oncology
University of Washington School of
Medicine/Seattle Cancer Care Alliance
Member, Clinical Research Division
Fred Hutchinson Cancer Research Center
Seattle, Washington
Contracted Research: Amgen Inc, Genentech BioOncology, Novartis Pharmaceuticals Corporation, Roche Laboratories Inc.
Sara A Hurvitz, MD
Assistant Clinical Professor of Medicine
University of California, Los Angeles
Director, Breast Oncology Program
Medical Director, Clinical Research Unit
Jonsson Comprehensive Cancer Center
Los Angeles, California
Contracted Research: Boehringer Ingelheim Pharmaceuticals Inc, Eisai Inc, Genentech BioOncology, GlaxoSmithKline, Novartis Pharmaceuticals Corporation, Roche Laboratories Inc, Sanofi; Paid Travel: Novartis Pharmaceuticals Corporation.
Ian E Krop, MD, PhD
Associate Physician, Dana-Farber Cancer Institute
Assistant Professor of Medicine
Harvard Medical School
Boston, Massachusetts
Advisory Committee: Seattle Genetics; Clinical Trial Support: Genentech BioOncology.
Kathy D Miller, MD
Co-Director, IU Simon Cancer Center
Breast Cancer Team
Ballvé Lantero Scholar in Oncology
Associate Professor of Medicine
Department of Personalized Medicine
Division of Hematology/Oncology
The Indiana University Melvin and
Bren Simon Cancer Center
Indianapolis, Indiana
Consulting Agreements: Antigen Express, Nektar; Contracted Research: Genentech BioOncology, ImClone Systems, a wholly owned subsidiary of Eli Lilly and Company; Paid Research: Antigen Express, Clovis Oncology, EntreMed Inc, Merrimack Pharmaceuticals, Syndax Pharmaceuticals Inc, Taiho Pharmaceutical Co Ltd.
Hyman B Muss, MD
Professor of Medicine
University of North Carolina
Director of Geriatric Oncology
Lineberger Comprehensive Cancer Center
Chapel Hill, North Carolina
Consulting Agreements: Pfizer Inc, Sanofi.
Joyce O'Shaughnessy, MD
Co-Director, Breast Cancer Research Program
Baylor-Charles A Sammons Cancer Center
Texas Oncology
US Oncology
Dallas, Texas
Advisory Committee: Genentech BioOncology; Consulting Agreements: Arno Therapeutics Inc, Eisai Inc, GlaxoSmithKline, Johnson & Johnson Pharmaceuticals, Roche Laboratories Inc, Sanofi.
Mark D Pegram, MD
Susy Yuan-Huey Hung Professor of Medicine
Director of the Breast Oncology Program
Director, Molecular Therapeutics Program
Stanford Cancer Institute
Stanford University School of Medicine
Stanford, California
Advisory Committee: Celgene Corporation, Genentech BioOncology; Consultant (Spouse): DAVA Oncology; Consulting Agreement: Genentech BioOncology; Contracted Research: Genentech BioOncology; Expert Testimony: Novartis Pharmaceuticals Corporation.
Hope S Rugo, MD
Professor of Medicine
Director, Breast Oncology and Clinical Trials Education
University of California, San Francisco
Helen Diller Family Comprehensive Cancer Center
San Francisco, California
Contracted Research: Agensys Inc, a subsidiary of Astellas Pharma US, Amgen Inc, Eisai Inc, Genentech BioOncology, GlaxoSmithKline, ImClone Systems, a wholly owned subsidiary of Eli Lilly and Company, MacroGenics Inc, Merck, Novartis Pharmaceuticals Corporation, Plexxikon Inc; Speakers Bureau: Genomic Health Inc.
CONSULTING COMMUNITY ONCOLOGISTS:
Mary Ann K Allison, MD
Comprehensive Cancer Centers of Nevada
Stephanie Campus
Henderson, Nevada
No real or apparent conflicts of interest to disclose.
Alan B Astrow, MD
Director, Division of Medical Oncology/Hematology
Maimonides Cancer Center
Brooklyn, New York
No real or apparent conflicts of interest to disclose.
Patricia A DeFusco, MD
Senior Staff, Department of Medicine
Hartford Hospital
Assistant Clinical Professor in the Department of Medicine
University of Connecticut School of Medicine
Hartford, Connecticut
No real or apparent conflicts of interest to disclose.
EDITOR — Dr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Algeta US, Allos Therapeutics, Amgen Inc, ArQule Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, Biodesix Inc, Biogen Idec, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Daiichi Sankyo Inc, Dendreon Corporation, Eisai Inc, EMD Serono Inc, Exelixis Inc, Foundation Medicine Inc, Genentech BioOncology, Genomic Health Inc, Gilead Sciences Inc, Incyte Corporation, Lilly, Medivation Inc, Merck, Millennium: The Takeda Oncology Company, Mundipharma International Limited, Novartis Pharmaceuticals Corporation, Novocure, Onyx Pharmaceuticals Inc, Prometheus Laboratories Inc, Regeneron Pharmaceuticals, Sanofi, Seattle Genetics, Spectrum Pharmaceuticals Inc and Teva Oncology.
RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no real or apparent conflicts of interest to disclose.
This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.
This activity is supported by educational grants from Genentech BioOncology and Novartis Pharmaceuticals Corporation.
Hardware/Software Requirements:
A high-speed Internet connection
A monitor set to 1280 x 1024 pixels or more
Internet Explorer 7 or later, Firefox 3.0 or later, Chrome, Safari 3.0 or later
Adobe Flash Player 10.2 plug-in or later
Adobe Acrobat Reader
(Optional) Sound card and speakers for audio
Last review date: December 2013
Expiration date: December 2014
A case-based Grand Rounds presentation featuring perspectives from Dr Hope S Rugo. 67:58 minutes. |
(WIFI is recommended for best performance):